Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
2.150
-0.030 (-1.38%)
At close: Oct 17, 2025, 4:00 PM EDT
2.150
0.00 (0.00%)
Pre-market: Oct 20, 2025, 5:20 AM EDT
Senti Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
34
Market Cap
56.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.56M | -1.73M | -40.25% |
| Dec 31, 2022 | 4.29M | 1.53M | 55.23% |
| Dec 31, 2021 | 2.76M | 2.20M | 387.81% |
| Dec 31, 2020 | 566.00K | 481.00K | 565.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SNTI News
- 3 days ago - Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference - GlobeNewsWire
- 13 days ago - Senti Bio to Present at BioJapan - GlobeNewsWire
- 4 weeks ago - Senti Bio to Present at the MedInvest Biotech & Pharma Conference - GlobeNewsWire
- 6 weeks ago - Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 2 months ago - Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - GlobeNewsWire
- 2 months ago - Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia - GlobeNewsWire